Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of unresectable or metastatic HER2 positive breast cancer. Update November 2022

Rothschedl, E. and Wolf, S. (2022): Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of unresectable or metastatic HER2 positive breast cancer. Update November 2022. Oncology Fact Sheet Nr. 102.

[thumbnail of Oncology Fact Sheet Nr.102_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
112kB

Item Type:	Horizon Scanning of Medicines
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WP Gynaecology > WP 800-910 Breast
Language:	English
Series Name:	Oncology Fact Sheet Nr. 102
Deposited on:	26 Jul 2022 14:54
Last Modified:	10 Jul 2025 11:34

Repository Staff Only: item control page